Cipla Limited has informed the Exchange about Investor Presentation
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Cipla delivered highest-ever yearly revenue of INR 28,163 Cr in FY26, up 2.2% YoY, despite multiple headwinds. However, Q4FY26 showed revenue decline of 3% YoY to INR 6,541 Cr. EBITDA margin contracted significantly - Q4 margins dropped to 15.2% from 22.8% in Q4FY25, and full year margins fell to 21.0% from 25.9% in FY25. PAT declined sharply by 55% YoY in Q4 to INR 555 Cr. The company maintains a strong net cash position of over INR 11,140 Cr on its balance sheet. Key developments include receiving approval for the first AB-rated gVentolin with CGT and Foracort crossing the INR 1,000 Cr milestone in IPM. North America delivered $483 Mn revenue with Albuterol ranked #1 at 19.6% market share.
The significant margin contraction in Q4 and FY26 may concern shareholders despite record revenue. However, strong cash reserves and upcoming launches like gVentolin provide potential catalysts. The near-term outlook remains challenging due to pricing pressures and market headwinds.